Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients

NCT04134026 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

400

Enrollment

OTHER

Sponsor class

Conditions

Anemia in Incident Dialysis Patients

Interventions

DRUG: HIF-PHI
DRUG: Epoetin Alfa

Sponsor

Second Xiangya Hospital of Central South University